- ¥6bn
- ¥1bn
- ¥8m
Annual income statement for Noile-Immune Biotech, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Yuho | Yuho |
| Standards: | JAS | JAS | — | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 97.3 | 101 | 626 | 317 | 7.59 |
| Cost of Revenue | |||||
| Gross Profit | 94.3 | 77.8 | 619 | 315 | 7.39 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 728 | 868 | 732 | 1,092 | 1,077 |
| Operating Profit | -631 | -768 | -106 | -775 | -1,069 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -631 | -793 | -384 | -1,128 | -962 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -637 | -795 | -387 | -1,130 | -964 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -637 | -795 | -387 | -1,130 | -964 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -637 | -795 | -387 | -1,130 | -964 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -14.3 | -18.4 | -8.95 | -26.1 | -22.3 |
| Dividends per Share |